Genenta Science SPA (Genenta Science SPA) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Genenta Science SPA's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Genenta Science SPA's average Total Assets over the quarter that ended in Dec. 2023 was $26.66 Mil. Therefore, Genenta Science SPA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Genenta Science SPA Gross-Profit-to-Asset % Historical Data

The historical data trend for Genenta Science SPA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Gross-Profit-to-Asset % Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Genenta Science SPA's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Genenta Science SPA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Gross-Profit-to-Asset % falls into.

Genenta Science SPA Gross-Profit-to-Asset % Calculation

Genenta Science SPA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (35.422	+	24.37)	/ 2 )
	=	0	/	29.896
	=	0.00 %

Genenta Science SPA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (28.956	+	24.37)	/ 2 )
	=	0	/	26.663
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Genenta Science SPA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.